NHSE Interim treatment options

Message from Steve Williamson, NHS England Lead Cancer Pharmacist

29th April 2020 – NHSE Interim treatment options

 

Dear Colleague

You may have seen that NICE has published an updated table to the SACT clinical guideline NG161 listing many new Interim treatment options earlier this week. See https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381. There are a couple of points of clarification for providers to note:

  • Enzalutamide for prostate cancer states it is subject to confirmation, we can confirm enzalutamide is approved, and there is no need to check for confirmation. A Blueteq form for abiraterone for patients unable to tolerate enzalutamide will be made available in due course.
  • Gilteritinib is approved for relapsed /refractory AML and not newly diagnosed AML.
  • Nivolumab is approved in MSI-H colorectal cancer, the wording states ‘subject to confirmation’ we can confirm this is approved and there is no need to check for confirmation.
  • A blueteq form for polatuzumab will be released in due course as NHSE is currently working with the company to ensure there is stock available for the selected patient group.

We advise all these indications are to be billed through the usual specialised commissioning route, as there is additional COVID19 funding available for them.  Any drugs where we have changed the CDF pathway are not funded through CDF as there is separate COVID19 funding for them. We are pleased to note that the manufacturers of many of these drugs have worked with NHS England and offered additional discounts to support the NHS during COVID19.

Latest News

By BOPA on 5th August 2022

Don’t miss out, EARLY BIRD RATE until Monday 22nd August 2022

Don’t miss out, EARLY BIRD RATE until Monday 22nd August 2022 Our first in-person meeting in 3 years will be hosted at the world-renowned ACC in Liverpool, set in the…

Read article
By BOPA on 5th August 2022

Community Pharmacist Jackie Lewis – recently featured in the Chemist and Druggist

BOPA’s pioneering Community Pharmacist Jackie Lewis recently featured in the Chemist and Druggist where her work was described critical to the recovery of cancer services post-pandemic.  Jackie is the author…

Read article
By BOPA on 2nd August 2022

Publication update – National SACT regimen specific consent form – Colorectal update

Dear All, The consent form project team is pleased to announce that the colorectal SACT consent forms have been reviewed and updated. They are available on the CRUK website at:…

Read article
By BOPA on 29th July 2022

Message from the BOPA Research Committee

We are delighted to announce that we have received a record-breaking number of abstracts for the 2022 Symposium in Liverpool.  A crack team of markers are now in the process…

Read article

25th BOPA Symposium 2022

7th to 9th October 2022 at The ACC Liverpool

REGISTRATION NOW OPEN!
Members: www.bopa.org.uk/2022-members-symposium-link/
Non members: Contact Media1Productions: [email protected]
Please see Key information before for accommodation information.

DRAFT AGENDA
Please click here to view the latest agenda.

CONFERENCE FEES (includes VAT)
Early-bird rate applies up until Monday 22nd August 2022

Everything you need to know